Patient Order Intake

Use this form to submit new patient case information. Alternatively, you can call us during business hours.


TeleDaaS Hours of Operation are Mon-Fri: 9am-5pm (EST)

Phone: (303) 500 - 7766

Please provide a reliable number for us to reach you if additional information is needed. You may also contact the TeleDaaS team at (303) 500-7766.

Phone

Select or enter value
Caret IconCaret symbol

Enter "N/A" if not applicable

Select or enter value
Caret IconCaret symbol

Note: please only submit imaging for what is required for the treatment plan.

Note: please only submit imaging for what is required for the treatment plan.

Please select the Post-Treatment images your are submitting*

Note: please only submit imaging for what is required for the treatment plan.

Note: please only submit imaging for what is required for the treatment plan.

Friendly reminder to send the images to TeleDaaS if not done already

Do you want TeleDaaS to use its default dosing methods?*

Please note that the following are utilized as the default dosing methods:


  1. Lobar deliveries: The target of the dosimetry with be 250 Gy to the tumor based on a randomized controlled trial out of France(1).
  2. For selective deliveries (defined as delivery to ≤2 segments) we will dose 400 Gy to the perfused volume based on a multicenter retrospective pathologic correlation showing 100% complete pathologic response in patients reaching this threshold(2). Please note that although this method will be used for dosing the customers will receive data indicating the predicted dose to tumor and normal tissue.


References:

(1) Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17-29.

(2) Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580-583.

Enter "N/A" if not applicable

Enter "N/A" if not applicable

Enter "N/A" if not applicable

Enter "N/A" if not applicable

Enter "N/A" if not applicable